Hitting tumors
at their
Achilles heel
Our Focus
Our Science
A Bold Approach
A tumor's genome constantly evolves. This makes tumors incredibly difficult to target.
We identified the engines that drive all genome rearrangements in tumors.
Our unique screening and cellular platforms are generating first-in-class inhibitors that allow us to directly target the key vulnerability present in genetically-defined tumors.
Our Clinical Goal
Treating Smartly
Specific tumors have specific biological requirements.
Our targets are essential in these genetically-defined tumors.
Our inhibitors thus target tumor cells in a highly specific and personalised manner.
By leveraging epigenetic mechanisms, we can now address unmet clinical needs.
We strive for better cures
Now is the time to leverage
the power of genomics
to develop the right drugs
for the right patients.
Our Management Team
In our team we combine proprietary scientific knowledge of our target enzymes, in-depth understanding of drug discovery and broad executive experience
Adrian Schomburg
CEO
Co-Founder
Adrian Schomburg, PhD, is a drug discovery expert with over 10 years of experience in pharma and biotech. He moved projects successfully through drug discovery - from target identification to the delivery of preclinical and development candidates. In his former roles at Pfizer and Proteros, he kick-started collaborative R&D projects in epigenetics with big pharma.
Andreas Ladurner
CSO
Co-Founder
Prof. Andreas Ladurner, PhD, is a globally recognized expert in chromatin biology and metabolism. His pioneering discoveries include the discovery of bromodomain and macrodomain function, including the allosteric regulation of key epigenetic enzymes. He is Chair and Full Professor of Physiological Chemistry at the LMU in Munich.
![BMBF_CMYK_Gef_M [Konvertiert]](https://cdn.shortpixel.ai/client/q_glossy,ret_img,w_295,h_178/https://www.eisbach.bio/wp-content/uploads/2020/06/BMBF_gefoerdert_2017_en-295x178.jpg "BMBF_CMYK_Gef_M [Konvertiert]")
